{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:09Z","timestamp":1789473849299,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jval.2023.06.009","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T21:14:00Z","timestamp":1687986840000},"page":"1435-1439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Decade of Health Innovation: The Impact of New Medicines on Patient Health and the Implications for NICE\u2019s Size of Benefit Multiplier"],"prefix":"10.1016","volume":"26","author":[{"given":"Jason","family":"Shafrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha","family":"Quddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moises","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Scanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jval.2023.06.009_bib1","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1056\/NEJMp1806283","article-title":"Innovation for pandemics","volume":"378","author":"Gates","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6534","key":"10.1016\/j.jval.2023.06.009_bib2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1126\/science.abg0889","article-title":"Market design to accelerate COVID-19 vaccine supply","volume":"371","author":"Castillo","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jval.2023.06.009_bib3","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-020-19505-2","article-title":"The once and future gene therapy","volume":"11","author":"Bulaklak","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jval.2023.06.009_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hec.4236","article-title":"Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year","volume":"30","author":"Nielsen","year":"2021","journal-title":"Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2023.06.009_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hec.1690","article-title":"Scope insensitivity in contingent valuation studies of health care services: should we ask twice?","volume":"21","author":"Gyrd-Hansen","year":"2012","journal-title":"Health Econ"},{"issue":"6","key":"10.1016\/j.jval.2023.06.009_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s10198-017-0929-z","article-title":"Estimating a constant WTP for a QALY\u2014a mission impossible?","volume":"19","author":"Sund","year":"2018","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2023.06.009_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhealeco.2011.09.004","article-title":"GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation","volume":"31","author":"Bobinac","year":"2012","journal-title":"J\u00a0Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2023.06.009_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.healun.2011.11.020","article-title":"Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease","volume":"31","author":"Andersen","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.jval.2023.06.009_bib17","doi-asserted-by":"crossref","first-page":"00591","DOI":"10.1183\/23120541.00591-2021","article-title":"Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"8","author":"Zheng","year":"2022","journal-title":"ERJ Open Res"},{"issue":"10","key":"10.1016\/j.jval.2023.06.009_bib18","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jval.2020.05.016","article-title":"Cost-effectiveness of ivacaftor therapy for treatment of cystic fibrosis patients with the G551D gating mutation","volume":"23","author":"Wherry","year":"2020","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2023.06.009_bib19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamaophthalmol.2019.2512","article-title":"Cost-effectiveness of voretigene neparvovec-rzyl vs standard care for RPE65-mediated inherited retinal disease","volume":"137","author":"Johnson","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jval.2023.06.009_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhealeco.2020.102346","article-title":"Health technology assessment with risk aversion in health","volume":"72","author":"Lakdawalla","year":"2020","journal-title":"J\u00a0Health Econ"},{"issue":"3","key":"10.1016\/j.jval.2023.06.009_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10198-021-01367-0","article-title":"A\u00a0guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE)","volume":"23","author":"Lakdawalla","year":"2022","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2023.06.009_bib22","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1017\/S0266462323000053","article-title":"Novel approach to decision making for orphan drugs","volume":"39","author":"Decker","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"issue":"24","key":"10.1016\/j.jval.2023.06.009_bib23","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2018.6072","article-title":"QALYs in 2018\u2014advantages and concerns","volume":"319","author":"Neumann","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jval.2023.06.009_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cpt.1565","article-title":"A\u00a0comparison of EMA and FDA\u00a0decisions for new drug marketing applications 2014-2016: concordance, discordance, and why","volume":"107","author":"Kashoki","year":"2020","journal-title":"Clin Pharmacol Ther"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523030267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523030267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:32:15Z","timestamp":1761096735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301523030267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1098301523030267"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.06.009","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Decade of Health Innovation: The Impact of New Medicines on Patient Health and the Implications for NICE\u2019s Size of Benefit Multiplier","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}